 Neutrophil engraftment is faster with ex vivo expanded NiCord than standard UCB  NiCord transplant is associated with decreased infection in the first 100 days  NiCord transplant is also associated with decreased early hospitalization
Introduction:
Umbilical cord blood (UCB) extends the curative potential of stem cell transplantation to adult patients without an HLA compatible donor. 1 After UCB transplantation, overall survival is comparable to matched related or unrelated donor transplantation, but treatment related mortality is significantly higher. 2, 3 UCB grafts are limited by low total and stem cell doses that are associated with delayed hematopoietic and immunologic recovery. Delayed neutrophil engraftment likely contributes to increased risk of life-threatening infection and longer hospitalization in the early post-UCB transplantation period. 4, 5 In order to overcome the limitation of low UCB cell dose, several techniques have been developed to expand cord blood-derived hematopoietic stem and progenitor cells ex vivo prior to transplantation. 6, 7 While each technique employs a different mechanism for ex vivo expansion, all have shown promise in reducing the time to neutrophil and platelet engraftment. [8] [9] [10] [11] NiCord is an UCB-derived cell product that uses a small molecule, nicotinamide, to inhibit differentiation and enhance functionality of hematopoietic stem and progenitor cells (HSPC) expanded in ex vivo culture. 12 The
NiCord graft consists of two fractions from the UCB unit. The CD133 positive fraction earlier median neutrophil recovery compared to historical controls, and long term engraftment with the NiCord unit was also observed in the majority of patients. 10 Rapid neutrophil recovery has also been observed in a subsequent ongoing phase II trial exploring the use of NiCord as a single unit graft. 13 Since use of the NiCord ex vivo expanded UCB graft resulted in rapid hematopoietic recovery, we hypothesized that NiCord transplantation would improve clinically relevant early outcomes by decreasing risk of infection and length of hospitalization. Therefore, we analyzed infection episodes and hospitalization during the first 100 days after transplantation in an enlarged cohort of patients undergoing
NiCord transplantation compared to a historical control of consecutive adult patients undergoing standard UCB transplantation at our institution.
Methods:
Patients and Transplantation Approach: Hospitalization was defined as "days alive and out of the hospital in the first 100 days" in order to account for the incongruous association of earlier mortality with shorter hospitalization, as previously reported by Ballen and colleagues. 5 For patients who survived to day 100, "days alive and out of the hospital in the first 100 days" was calculated by subtracting the total number of days in the hospital during the initial admission and any readmissions from 100. For patients who died before day 100, "days alive and out of the hospital in the first 100 days" was calculated by subtracting the total number of days in the hospital during the initial admission and any readmissions from the day of transplantation to the day of death. In this way, if a patient's death occurred during the initial hospitalization, then there were no days alive and out of the hospital.
Statistical Analysis:
Patient baseline and transplant characteristics were compared using the Fisher's exact test and t-test for categorical and continuous variables, respectively. The cumulative incidence of neutrophil recovery was compared between study groups with death, relapse, or subsequent transplant as competing risks, and the hazard ratio (HR) and 95% confidence interval (CI) for study group was estimated from a proportional hazards model that also accounted for competing risks. Infection rates were calculated as the number of patients who experienced each infection at least one time during their observation period, and Fisher's exact tests were used to test for differences between groups. To account for multiple infections in an individual patient as well as differing periods of risk, infection densities were calculated as the total number of infections per patient per days at risk. Individual patient infection densities were then averaged over all patients in a group to calculate the mean number of infections experienced per 100 patient days, and Wilcoxon rank-sum tests were used to test for differences between groups. Poisson regression was used to estimate the effect of NiCord versus standard UCB transplantation on the rates of total infection, grade 2-3 infection, bacterial infection, grade 2-3 bacterial infection, and grade 2-3 non-viral infection, both univariately and after adjustment for covariates known to affect the risk of infection including age, disease status, and acute GVHD. 16 An offset was included in the model to account for the observation time for each patient. Risk ratios (RR) and 95% CI were 
Results:
Patients:
A total of 104 patients were included in this study; 18 underwent NiCord transplantation and 86 underwent standard UCB transplantation. Patient baseline and transplant characteristics are summarized in Table 1 . NiCord recipients were older (median age Infection Density:
The mean number of total infections during the first 100 days following transplantation was 3.7 per patient in the NiCord group and 4.9 per patient in the standard UCB transplantation group (p=0.09, Figure 2a However, after adjustment, increasing age had no impact on length of hospitalization.
Discussion:
Delayed hematopoietic recovery remains a major limitation of umbilical cord blood transplantation. Several methods for ex vivo expansion of UCB units before transplantation have resulted in improved time to neutrophil engraftment, but the impact on clinically relevant early outcomes has not been evaluated. As previously reported in the Phase 1 trial of NiCord transplantation, we found that transplantation of the ex vivo expanded NiCord graft in an enlarged cohort was associated with rapid hematopoietic recovery compared to a historical cohort of patients undergoing standard UCB transplantation. In this study, we show that early hematopoietic recovery in NiCord recipients translates into a decreased burden of infectious complications and hospitalization in the first 100 days after transplantation.
A recent analysis of infectious complications from the randomized BMT CTN 0201 study comparing bone marrow to peripheral blood stem cells from unrelated donors showed a higher cumulative incidence of infection before engraftment and bacterial bloodstream infection during the first 100 days in the bone marrow group, which also had a 5 day longer median time to neutrophil engraftment. 17, 18 Several prior studies have reported a higher incidence of bacterial and fungal infections during the post-transplantation period in UCB transplantation recipients compared to other unrelated donor sources. 4, [19] [20] [21] A large registry analysis of UCB transplantation identified an association between early bacterial infection and increased risk of overall mortality, although another analysis comparing overall infection related mortality between UCB and other unrelated donor sources did not identify a significant difference. 4, 22 Regardless, decreasing morbidity and resource utilization associated with early infectious complications is a clinically relevant outcome.
In the current study, we identified an early bacterial infection rate of 2.0 per patient during the first 100 days in the standard UCB group, which is similar to the previously reported rate of 2.1 bacterial infections per patient in the first 100 days after UCB transplantation by Parody and colleagues, recognizing that there are some subtle differences in the method of categorizing infections. 4 By contrast, in the NiCord transplantation group, the rate of early bacterial infection was significantly decreased to 0.68 infections per patient, and this effect remained unchanged after adjusting for age, disease stage, and acute GVHD. Similarly, clinically significant grade 2-3 total and bacterial infection rates were also lower in the NiCord group compared to the standard UCB group in our analysis. The difference in moderate to severe bacterial infection was largely due to a decrease in bloodstream infection in the NiCord group, which may be a function of earlier neutrophil recovery. Bloodstream infection is the most common infection after allogeneic transplantation and has been associated with increased mortality. 23 In addition, antibiotic use that accompanies these infections may have a negative impact on intestinal bacterial flora. Recent studies have shown that broad spectrum antibiotic therapy can alter the intestinal microbiome, and low microbial diversity has been associated with increased acute GVHD and mortality after transplantation [24] [25] [26] . Therefore, the benefits of early engraftment may extend beyond reduction in the morbidity and mortality associated with bloodstream infections.
Conversely, there was no difference between the NiCord and standard UCB group in the rate of viral infection, which would not necessarily be expected with earlier hematologic recovery. The paradoxical protective effect of grade II-IV acute GVHD in our multivariate model was likely related to the significantly higher proportion of patients without acute grade II-IV GVHD who experienced primary graft failure and subsequently requiring a second rescue transplant. This resulted in an increased risk of infectious complications due to prolonged neutropenia.
A recent registry analysis comparing hospitalization between unrelated donor graft sources showed that double UCB recipients had a median of 55 days alive and out of the hospital in the first 100 days after transplantation, significantly shorter than median 75 days for peripheral blood stem cell graft recipients. 5 In our study, NiCord recipients had an adjusted mean of 69.9 days alive and out of the hospital in the first 100 days, significantly longer than 49.7 days in the standard UCB transplantation group.
It is tempting to speculate that faster neutrophil engraftment and decreased infectious complications may be contributing to the improvement in time out of the hospital in the NiCord group.
Limitations of this study include the small sample size in the NiCord group and the inherent inability to control for all potential confounding factors in a retrospective analysis. However, since all the included patients were treated at a single institution, there is a lower risk of unaccounted differences in supportive care. In order to evaluate the potential impact of changes in supportive care over time, we performed a sensitivity analysis comparing NiCord patients to a contemporaneous cohort of standard UCB patients transplanted from 2010-2015, which did not differ from the primary analysis of infection density or hospitalization. The current analysis included detailed infection data that is generally not available in a larger registry based study. Larger studies will be required to determine if improved early clinical outcomes after NiCord transplantation compared to standard UCB recipients will translate into improved overall patient outcomes.
In conclusion, transplantation of NiCord was associated with faster neutrophil engraftment, reduced total and bacterial infections, and shorter hospitalization in the first 100 days after transplantation compared to standard UCB transplantation. Our results confirm that rapid hematopoietic recovery from an ex vivo expanded UCB transplantation approach is associated with early clinical benefit. Non-microbiologically defined infection 9 60
Uncomplicated fever with negative cultures 9 43
Pneumonia without an identified organism 0 17
1 weekly PCR surveillance for CMV viremia during entire study period 2 weekly PCR surveillance for HHV-6 viremia starting in 2010 
